{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":24,"sponsored":0,"items":[{"id":"n_oyt2aqw2mwnoxomycjlq","seq":1401224,"kind":"article","title":"Novartis Signs Deal With Abogen For MRNA Therapies","url":"https://www.finanzen.ch/nachrichten/aktien/novartis-signs-deal-with-abogen-for-mrna-therapies-1036594189","published":"2026-10-02T17:40:40Z","seen":"2026-10-02T17:40:40Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"health","category_p":0.42,"category2":"economy-business","sentiment":"positive","tone":0.18,"political":0.06},{"id":"n_wguc74jjzsyg5dtbt44a","seq":1391105,"kind":"article","title":"Novartis fecha acordo de até US$ 7,75 bi com chinesa Abogen para desenvolver medicamentos","title_en":"Novartis signs up to $7.75 billion agreement with Chinese Abogen to develop medicines","url":"https://redir.folha.com.br/redir/online/emcimadahora/rss091/*https://c-level.folha.uol.com.br/negocios/2026/10/novartis-fecha-acordo-de-ate-us-775-bi-com-chinesa-abogen-para-desenvolver-medicamentos.shtml","summary":"A farmacêutica suíça Novartis fechou um acordo com o laboratório chinês Abogen Biosciences para desenvolver conjuntamente medicamentos de RNA, incluindo um possível novo tratamento para doenças autoimunes, informaram as empresas nesta sexta-feira (2). Leia mais (10/02/2026 - 13h42)","published":"2026-10-02T16:42:00Z","seen":"2026-10-02T16:53:28Z","lang":"pt","country":"BR","source":{"id":"kite-folha-uol-com-br-a7488b","name":"folha.uol.com.br","domain":"feeds.folha.uol.com.br"},"via":"kite-folha-uol-com-br-a7488b","entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.75,"sentiment":"positive","tone":0.39,"political":0.09},{"id":"n_natocqcnpb6i3b4rzkkq","seq":1367649,"kind":"article","title":"Novartis pays Abogen $575m for mRNA programs","url":"https://www.bioxconomy.com/partnering/abogen-lands-7-8bn-novartis-partnership-for-autoimmune-platform","published":"2026-10-02T13:30:00Z","seen":"2026-10-02T14:47:20Z","lang":"en","source":{"id":"bioxconomy.com","name":"bioxconomy.com","domain":"bioxconomy.com","outlet":{"wikidata":"Q135641054","name":"BioXconomy","type":"magazine","country":"US","designations":["business","news media","trade magazine"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dcgwqnkz3gb62g5mw6tq","category":"economy-business","category_p":0.54,"sentiment":"positive","tone":0.72,"political":0.06},{"id":"n_eg2k4o6iz7igmc5zx6ta","seq":1349770,"kind":"article","title":"Novartis licencia medicamento da chinesa Abogen em acordo de até US$ 7,8 bilhões","title_en":"Novartis licenses Chinese Abogen drug in up to $7.8 billion deal","url":"https://valor.globo.com/empresas/noticia/2026/10/02/novartis-licencia-medicamento-da-chinesa-abogen-em-acordo-de-at-us-78-bilhes.ghtml","summary":"A Novartis fechou um acordo avaliado em até US$ 7,8 bilhões para licenciar um candidato a medicamento da chinesa Abogen Biosciences e obter opções sobre futuras terapias, na mais recente parceria entre uma grande farmacêutica ocidental e uma empresa chinesa emergente. Matéria exclusiva para assinantes. Para ter acesso completo, acesse o link da matéria e faça o seu cadastro.","published":"2026-10-02T12:21:16Z","seen":"2026-10-02T13:17:20Z","lang":"pt","country":"BR","source":{"id":"kite-pox-globo-com-4344ca","name":"pox.globo.com","domain":"pox.globo.com"},"via":"kite-pox-globo-com-4344ca","topics":["valor"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"image":"https://s2-valor.glbimg.com/aDlR4pscGzbqo1pefJeeWDir-j0=/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2025/h/D/xuqQfCSEKoYkkxsTzKDw/432052593.jpg","story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.69,"sentiment":"positive","tone":0.26,"political":0.1},{"id":"n_oxyapy2tuezfoi6ilrwq","seq":1343940,"kind":"article","title":"Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal — Update","url":"https://www.morningstar.com/news/dow-jones/202610022725/novartis-to-license-drug-from-chinas-abogen-in-up-to-78-billion-deal-update","published":"2026-10-02T12:15:00Z","seen":"2026-10-02T12:41:46Z","lang":"en","source":{"id":"morningstar.com","name":"morningstar.com","domain":"morningstar.com","outlet":{"wikidata":"Q1389504","name":"Morningstar, Inc.","type":"other","country":"US","designations":["business","database","pinnacle financial solutions ltd","public company"]}},"via":"gdelt-gkg-english","entities":[{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q29520","name":"China","type":"place"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.78,"sentiment":"positive","tone":0.4,"political":0.12},{"id":"n_524vz5oksd3aevsq2slq","seq":1328066,"kind":"article","title":"Novartis signs mRNA deal for about $7.8 billion with China's Abogen","url":"https://www.ksl.com/article/51631446/novartis-signs-mrna-deal-for-about-78-billion-with-chinas-abogen","published":"2026-10-02T11:15:00Z","seen":"2026-10-02T11:19:26Z","lang":"en","source":{"id":"ksl.com","name":"ksl.com","domain":"ksl.com","outlet":{"wikidata":"Q6337865","name":"KSL-TV","type":"broadcaster","country":"US","designations":["television station"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.61,"sentiment":"positive","tone":0.4,"political":0.11},{"id":"n_jrxestvtulj27mnbygpq","seq":1331186,"kind":"article","title":"Novartis signs $7.8 billion Abogen biotech licensing deal","url":"https://www.cnbc.com/2026/10/02/novartis-abogen-china-biotech-deal.html","published":"2026-10-02T11:13:00Z","seen":"2026-10-02T11:39:19Z","lang":"en","source":{"id":"cnbc.com","name":"cnbc.com","domain":"cnbc.com","outlet":{"wikidata":"Q1023912","name":"CNBC","type":"website","country":"US","designations":["business channel","cable channel","news website","specialty channel"]}},"via":"gdelt-gkg-english","topics":["economy","health","science"],"authors":["Elsa Ohlen"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.75,"sentiment":"positive","tone":0.24,"political":0.07},{"id":"n_dn52ddkhl4w7yigtwxua","seq":1303040,"kind":"article","title":"Novartis signs mRNA deal for about $7.8 billion with China's Abogen – KSEV Radio","url":"https://ksevradio.com/novartis-signs-mrna-deal-for-about-7-8-billion-with-chinas-abogen","published":"2026-10-02T09:00:00Z","seen":"2026-10-02T09:00:36Z","lang":"en","source":{"id":"ksevradio.com","name":"ksevradio.com","domain":"ksevradio.com","outlet":{"wikidata":"Q6337649","name":"KSEV","type":"broadcaster","country":"US","designations":["radio station"]}},"via":"gdelt-gkg-english","topics":["health","economy"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_dn52ddkhl4w7yigtwxua","category":"economy-business","category_p":0.65,"sentiment":"positive","tone":0.35,"political":0.19},{"id":"n_7ie35huug5knd43c3f5q","seq":1290070,"kind":"article","title":"Novartis erweitert mit Abogen-Lizenzabkommen RNA-Portfolio","title_en":"Novartis expands RNA portfolio with Abogen license agreement","url":"https://www.cash.ch/news/top-news/novartis-erweitert-mit-abogen-lizenzabkommen-rna-portfolio-973634","summary":"Pharmazie - Novartis sichert sich eine exklusive Lizenz für einen neuartigen Wirkstoff des chinesischen Biotech-Unternehmens Abogen.","published":"2026-10-02T06:59:15Z","seen":"2026-10-02T07:40:46Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/3089/1741/sites/default/files/images/library/novartis_pharma_0.jpg","story":"st_7ie35huug5knd43c3f5q","category":"economy-business","category_p":0.68,"category2":"science-technology","sentiment":"positive","tone":0.38,"political":0.04},{"id":"n_ny36satxpff7s6km2gma","seq":1271856,"kind":"article","title":"Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs","url":"https://www.prnewswire.com/news-releases/abogen-announces-licensing-and-option-agreement-with-novartis-to-advance-mrna-encoded-t-cell-engager-and-other-potential-rna-programs-302896950.html","published":"2026-10-02T05:40:41Z","seen":"2026-10-02T05:40:41Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","science","health"],"authors":["Abogen"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_ny36satxpff7s6km2gma","category":"science-technology","category_p":0.5,"category2":"economy-business","sentiment":"positive","tone":0.64,"political":0.04},{"id":"n_hx3v4kpbyz67iuubibuq","seq":900588,"kind":"article","title":"Πολάκης: «Φτάνει πια με το κουκούλωμα και την κοροϊδία για τα κλεμμένα δισεκατομμύρια της Novartis»","title_en":"Polakis: 'Enough already with the cover-up and mockery over the stolen billions of Novartis'","url":"https://www.zarpanews.gr/polakis-ftanei-pia-me-to-koykoyloma-kai-tin-koroidia-gia-ta-klemmena-disekatommyria-tis-novartis","summary":"Ο ελληνικός λαός στενάζει από την ακρίβεια, την ώρα που το καθεστώς της διαπλοκής και της συγκάλυψης παίζει θέατρο στις πλάτες της δημόσιας υγείας και του δημοσίου χρήματος. Όπως αποκαλύπτεται από το εξαιρετικώς επείγον εξώδικο και την επίσημη αναφορά που κατέθεσε για λογαριασμό του κόμματος ο Τομεάρχης Διαφάνειας Παύλος Πολάκης, με τη νομική συνδρομή του […] The post Πολάκης: «Φτάνει πια με το κουκούλωμα και την κοροϊδία για τα κλεμμένα δισεκατομμύρια της Novartis» appeared…","published":"2026-09-30T11:36:39Z","seen":"2026-09-30T12:27:48Z","lang":"el","country":"GR","source":{"id":"kite-zarpanews-gr-23a24d","name":"zarpanews.gr","domain":"zarpanews.gr"},"via":"kite-zarpanews-gr-23a24d","topics":["xania","novartis","βουλη","παυλος πολακης"],"authors":["ΜΙΧΑΛΗΣ ΚΑΛΑΡΝΤ"],"entities":[{"id":"Q152630","name":"4078 Polakis","type":"person"},{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_hx3v4kpbyz67iuubibuq","category":"politics","category_p":0.53,"sentiment":"negative","tone":-0.49,"political":0.53},{"id":"n_2f2k55tqgod7ydyzmlza","seq":862478,"kind":"press_release","title":"CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J","url":"https://www.globenewswire.com/news-release/2026/09/30/3371624/28124/en/car-t-cell-therapy-market-forecasts-growth-from-7-24b-2026-to-13-78b-by-2031-profiling-bristol-myers-squibb-gilead-sciences-novartis-j-j.html","summary":"The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.…","published":"2026-09-30T08:47:00Z","seen":"2026-09-30T08:56:58Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_2f2k55tqgod7ydyzmlza","category":"health","category_p":0.48,"category2":"economy-business","sentiment":"neutral","tone":0.15,"political":0.02},{"id":"n_rqdhm5euqz27edc6syqa","seq":773576,"kind":"press_release","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS","url":"https://www.globenewswire.com/news-release/2026/09/29/3371428/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-novartis-ag-nvs.html","summary":"NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.","published":"2026-09-29T21:39:00Z","seen":"2026-09-29T21:52:44Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_7hliboa3ppj4wgmnafea","category":"economy-business","category_p":0.65,"sentiment":"neutral","tone":-0.26,"political":0.2},{"id":"n_sr3jcq7iqmti3zkbaaxa","seq":702432,"kind":"article","title":"CAS announces collaboration with Novartis to advance AI-ready reaction informatics","url":"https://www.manilatimes.net/2026/09/29/tmt-newswire/pr-newswire/cas-announces-collaboration-with-novartis-to-advance-ai-ready-reaction-informatics/2435382","published":"2026-09-29T14:25:00Z","seen":"2026-09-29T15:12:54Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","science"],"entities":[{"id":"Q911173","name":"Chemical Abstracts Service","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_kivl4pwiee7yiormgtga","category":"science-technology","category_p":0.88,"sentiment":"positive","tone":0.7,"political":0.13},{"id":"n_km7hmkycr73n7aidns2q","seq":667962,"kind":"article","title":"Fire Reported At Penn State Frat House | News Radio 1400 WRAK","url":"https://wrak.iheart.com/content/2026-09-29-fire-reported-at-penn-state-frat-house","published":"2026-09-29T12:26:24Z","seen":"2026-09-29T12:26:24Z","lang":"en","source":{"id":"iheart.com","name":"iheart.com","domain":"iheart.com","outlet":{"wikidata":"Q793699","name":"iHeartRadio","type":"broadcaster","country":"CA","designations":["dot-com company","internet radio","podcast directory"]}},"via":"gdelt-gkg-english","topics":["economy","education"],"entities":[{"id":"Q911173","name":"Chemical Abstracts Service","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_km7hmkycr73n7aidns2q","category":"disaster-accident","category_p":0.35,"sentiment":"negative","tone":-0.51,"political":0.2},{"id":"n_msughiecpj6n4vegaoja","seq":582015,"kind":"article","title":"恒瑞醫藥向諾和授許可 潛在總交易額最高達26億美元","title_en":"Hengrui Medicine grants license to Novartis with potential total transaction value up to $2.6 billion","url":"https://www.bastillepost.com/hongkong/article/16869939-%e6%81%92%e7%91%9e%e9%86%ab%e8%97%a5%e5%90%91%e8%ab%be%e5%92%8c%e6%8e%88%e8%a8%b1%e5%8f%af-%e6%bd%9b%e5%9c%a8%e7%b8%bd%e4%ba%a4%e6%98%93%e9%a1%8d%e6%9c%80%e9%ab%98%e9%81%9426%e5%84%84%e7%be%8e","summary":"恒瑞醫藥(01276)發公告，披露與諾和達成授權許可協議，向對方授予HRS-1596在大中華地區以外全球開發、生產與商業化的獨家權利。 公告指出，恒瑞醫樂在交易在潛在獲得金額最高達26億美元，包括3億美元首付款，以及達成相關開發、註冊和商業化里程碑後獲得的付款。該公司尚有資格根據HRS-1596在授權區域內淨銷售額，收取相應銷售提成。 HRS-1596 是一款恒瑞自主研發的GLP-1/GIP雙受體激動劑。HRS-1596旨在通過抑制食欲、促進胰島素分泌和改善胰島素敏感性等多重機制，實現減重和改善血糖控制，具有用於肥胖症、2型糖尿病及其他代謝性疾病的潛力。","published":"2026-09-29T04:39:40Z","seen":"2026-09-29T05:10:20Z","lang":"zh","country":"HK","source":{"id":"kite-bastillepost-com-c7bf21","name":"bastillepost.com","domain":"bastillepost.com"},"via":"kite-bastillepost-com-c7bf21","topics":["錢財事","恒瑞醫藥(01276)"],"authors":["Tong Po Yan"],"entities":[{"id":"Q24838676","name":"Jiangsu Hengrui Medicine","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_msughiecpj6n4vegaoja","category":"economy-business","category_p":0.94,"sentiment":"positive","tone":0.49,"political":0.12},{"id":"n_34n2xl24o2dvt66f5b4q","seq":550146,"kind":"article","title":"Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?","url":"https://www.insidermonkey.com/news/novartis-nvs-has-more-growth-ahead-can-its-portfolio-outrun-generic-pressure-1845526","published":"2026-09-29T00:43:39Z","seen":"2026-09-29T00:43:39Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","disaster","business","health"],"authors":["Laiba Immad"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_34n2xl24o2dvt66f5b4q","category":"economy-business","category_p":0.84,"sentiment":"neutral","tone":0.12,"political":0.01},{"id":"n_sy2ruopwtvg7i7h2anoa","seq":495795,"kind":"article","title":"Η Καρυστιανού απαντά στον Άδωνι με νανογιλέκα και Novartis: «Κάθε έλεγχος καλοδεχούμενος… για όλους όμως κ. Γεωργιάδη»","title_en":"Karystianou responds to Adonis with a nano-gillet and Novartis: 'Every inspection is welcome... but for all, Mr. Georgiadis'","url":"https://www.efsyn.gr/politiki/1476482/me-sfodri-epithesi-apanta-i-karystianoy-ston-adoni-kathe-eleghos-kalodehoymenos-gia-oloys-omos-k-georgiadi","summary":"«Και πρώτα από όλους για τα μέλη της Κυβέρνησής σας, που έχουν πνιγεί μέσα στις τόσες θαμμένες στα συρτάρια ποινικές δικογραφίες στην καμπούρα τους».","published":"2026-09-28T18:00:01Z","seen":"2026-09-28T18:27:21Z","lang":"el","country":"GR","source":{"id":"kite-efsyn-gr-5461e1","name":"efsyn.gr","domain":"efsyn.gr","outlet":{"wikidata":"Q20638209","name":"Efimerida ton Syntakton","type":"newspaper","designations":["newspaper"]}},"via":"kite-efsyn-gr-5461e1","topics":["αντιπολίτευση","πολιτική"],"authors":["Αριστείδης Αποστόλου"],"entities":[{"id":"Q147534","name":"Adonis","type":"person"},{"id":"Q507154","name":"Novartis","type":"org"}],"story":"st_qlbrcc2p3ik6tbdj6gcq","category":"politics","category_p":0.67,"sentiment":"neutral","tone":-0.05,"political":0.72},{"id":"n_224xifcnjaoe4a6c3gha","seq":462993,"kind":"article","title":"Novartis-Talent Vincent Track holt Silber bei WorldSkills 2026 in Shanghai","title_en":"Novartis talent Vincent Track wins silver at WorldSkills 2026 in Shanghai","url":"https://www.ots.at/presseaussendung/OTS_20260928_OTS0161/novartis-talent-vincent-track-holt-silber-bei-worldskills-2026-in-shanghai","summary":"Shanghai/Schaftenau (OTS) - Österreich-Premiere mit historischem Erfolg für Novartis-Mitarbeiter: Der Tiroler Vincent Track gewann bei den Berufsweltmeisterschaften WorldSkills 2026 in Shanghai die Silbermedaille...","published":"2026-09-28T14:37:32Z","seen":"2026-09-28T15:24:24Z","lang":"de","country":"AT","source":{"id":"kite-ots-at-7c6ddb","name":"ots.at","domain":"ots.at","outlet":{"wikidata":"Q91809962","name":"APA-OTS","type":"other","country":"AT","designations":["business","enterprise"]}},"via":"kite-ots-at-7c6ddb","authors":["author"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q8686","name":"Shanghai","type":"place"}],"story":"st_224xifcnjaoe4a6c3gha","category":"science-technology","category_p":0.32,"sentiment":"positive","tone":0.51,"political":0.03},{"id":"n_wzymb667qf7unsmnmtya","seq":466477,"kind":"article","title":"Börsen-Ticker: SMI schliesst knapp gehalten - Novartis legen zu - Logitech im Angebot - DocMorris gefragt - Biotech-Sektor knickt ein","title_en":"Stock market ticker: SMI closes narrowly held - Novartis rises - Logitech on offer - DocMorris in demand - Biotech sector buckles","url":"https://www.cash.ch/news/top-news/borsen-ticker-smi-schliesst-knapp-gehalten-novartis-legen-zu-logitech-im-angebot-docmorris-gefragt-biotech-sektor-knickt-ein-971972","summary":"+++Märkte+++ - Die Schweizer Börse ging am Montag unverändert aus dem Handel.","published":"2026-09-28T13:35:00Z","seen":"2026-09-28T15:52:12Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q223127","name":"Logitech","type":"org"},{"id":"Q669499","name":"DocMorris","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/546/362/sites/default/files/media/field_image/2025-08/novartis_fermentationsanlage.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.83,"sentiment":"neutral","tone":0.14,"political":0.02},{"id":"n_ghqfvkiy5q2lk7gxufsa","seq":452742,"kind":"article","title":"Börsen-Ticker: US-Märkte mit Abgaben - Nvidia gefragt - SMI knapp in der Gewinnzone - Novartis legen zu - DocMorris im Aufwind","title_en":"Stock market ticker: US markets with declines - Nvidia in demand - SMI barely in the profit zone - Novartis rises - DocMorris on the rise","url":"https://www.cash.ch/news/top-news/borsen-ticker-us-markte-mit-abgaben-nvidia-gefragt-smi-knapp-in-der-gewinnzone-novartis-legen-zu-docmorris-im-aufwind-971972","summary":"+++Märkte+++ - Die US-Märkte notieren mit Kursverlusten.","published":"2026-09-28T13:35:00Z","seen":"2026-09-28T14:50:29Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q182477","name":"Nvidia","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q669499","name":"DocMorris","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/2000/1331/sites/default/files/media/field_image/2023-08/wallstreet_wall_street_borse.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.88,"sentiment":"neutral","tone":0.2,"political":0.02},{"id":"n_tjk3vge7wlzpvjoho7pq","seq":414883,"kind":"article","title":"Börsen-Ticker: US-Märkte vor dem Start tiefer - SMI knapp im Plus - Novartis überzeugt - Roche im Hintertreffen","title_en":"Stock Market Ticker: US markets lower before start - SMI barely in the plus - Novartis impresses - Roche lags behind","url":"https://www.cash.ch/news/top-news/borsen-ticker-us-markte-vor-dem-start-tiefer-smi-knapp-im-plus-novartis-uberzeugt-roche-im-hintertreffen-971972","summary":"+++Märkte+++ - Die Vorzeichen für den Handel an der Wall Street stehen schlecht.","published":"2026-09-28T04:20:00Z","seen":"2026-09-28T11:47:20Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/2000/1331/sites/default/files/media/field_image/2023-08/wallstreet_wall_street_borse.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.85,"sentiment":"neutral","tone":-0.03,"political":0.04},{"id":"n_ifju3f5on45tbipfg6dq","seq":391634,"kind":"article","title":"Börsen-Ticker: SMI im Plus - Novartis stark - Roche fällt ins Minus - UBS weiter gefragt - Bitcoin fällt","title_en":"Stock market ticker: SMI in the plus - Novartis strong - Roche falls into the minus - UBS still in demand - Bitcoin falls","url":"https://www.cash.ch/news/top-news/borsen-ticker-smi-im-plus-novartis-stark-roche-fallt-ins-minus-ubs-weiter-gefragt-bitcoin-fallt-971972","summary":"+++Märkte+++ - Am Schweizer Aktienmarkt herrscht zum Wochenauftakt eine freundliche Stimmung.","published":"2026-09-28T04:20:00Z","seen":"2026-09-28T09:46:26Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q1432699","name":"Samos International Airport","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q193199","name":"UBS","type":"org"},{"id":"Q131723","name":"Bitcoin","type":"other"}],"image":"https://www.cash.ch/fp/1200/675/415/238/sites/default/files/images/library/six_zuerich_boerse_3.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.85,"sentiment":"neutral","tone":0.12,"political":0.05},{"id":"n_7fcr7v5zisztpkwcqpxa","seq":369132,"kind":"article","title":"Börsen-Ticker: SMI über 14'000 Punkte - Neue Kursziele und Rating - Roche und Novartis stark - ABB und Logitech im Rückwärtsgang","title_en":"Stock market ticker: SMI over 14,000 points - New price targets and ratings - Roche and Novartis strong - ABB and Logitech in reverse","url":"https://www.cash.ch/news/top-news/borsen-ticker-smi-uber-14000-punkte-neue-kursziele-und-rating-roche-und-novartis-stark-abb-und-logitech-im-ruckwartsgang-971972","summary":"+++Märkte+++ - Am Schweizer Aktienmarkt herrscht zum Wochenauftakt eine freundliche Stimmung.","published":"2026-09-28T04:20:00Z","seen":"2026-09-28T07:43:03Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q30258448","name":"ABB","type":"org"},{"id":"Q223127","name":"Logitech","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/415/238/sites/default/files/images/library/six_zuerich_boerse_3.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.9,"sentiment":"neutral","tone":0.34,"political":0.06}]}